MET and non-small cell lung carcinoma: To further investigate the promising clinical activity demonstrated by selective MET inhibitors, such as savolitinib and crizotinib, an ongoing phase II clinical trial (NCT02019693) is assessing the antitumor response of pRCC patients to capmatinib, a selective MET inhibitor currently approved for treating non-small cell lung cancer (52).